Teva Taps Board Member Elstein For Biogenerics VP Post
This article was originally published in The Pink Sheet Daily
The appointment could reflect a significant push toward the development of follow-on biologics. The generic firm announces several personnel changes, including promotions of its top North America officers.
You may also be interested in...
Congress will take up the issue of "follow-on" biologics in 2004, generic drug maker Teva predicts
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.
Three FDA risk management final guidances recommend that sponsors collect a wide range of safety data during both the clinical trial and postmarketing periods of drug development. The agency suggests that sponsors hold discussions with FDA before settling on drug study designs or postmarketing activities.